The RNF14 antibody targets the RING finger protein 14 (RNF14), a member of the E3 ubiquitin ligase family characterized by a conserved RING finger domain that facilitates protein-protein interactions and ubiquitination. RNF14 plays a multifaceted role in cellular processes, including transcriptional regulation, DNA damage repair, and hormone signaling pathways, particularly interacting with androgen and estrogen receptors. It is implicated in modulating nuclear receptor activity by promoting ligand-dependent degradation or stabilization of target proteins, linking it to hormone-related cancers like prostate and breast cancer.
Antibodies against RNF14 are essential tools for studying its expression, localization, and function in both normal and pathological contexts. They are widely used in techniques such as Western blotting, immunohistochemistry, and co-immunoprecipitation to explore RNF14’s involvement in oncogenesis, metabolic regulation, and cellular stress responses. Commercial RNF14 antibodies are typically validated for specificity and cross-reactivity across human, mouse, and rat samples. Research utilizing these antibodies has highlighted RNF14’s dual roles as a potential tumor suppressor or promoter, depending on cellular context, making it a focus for therapeutic targeting. Recent studies also suggest its interaction with viral proteins, expanding its relevance to infectious disease research.